Business context and reporting period
The filing is Clorox’s Form 10-K for the fiscal year ended June 30, 2021, not a 2020 fourth-quarter filing. Clorox is a multinational consumer and professional products company with about 9,000 employees; more than 80% of sales come from brands holding a No. 1 or No. 2 position in their categories. Its four reportable segments are Health and Wellness, Household, Lifestyle and International.
Financial performance and key metrics
| Metric | Reported information |
|---|---|
| Net sales | $7.3 billion; up 9% in fiscal 2021 |
| Diluted EPS | Down 24%; the provided filing text does not give the absolute amount |
| Profit, cash flow and margins | The provided text does not give clear values. Financial statements and detailed MD&A are incorporated by reference in Exhibit 99.1, which is not included here. |
| Debt | Nearly $3 billion as of June 30, 2021 |
| Dividends | $558 million paid in fiscal 2021; quarterly dividend increased 5% in June 2021 |
| Environmental remediation liability | $28 million at June 30, 2021, unchanged from June 30, 2020 |
Material changes and unusual items
- COVID-19-related demand for essential household products, particularly cleaning and disinfecting products, supported sales growth. The company also reported supply challenges and higher manufacturing, logistics and commodity costs.
- Clorox recorded a $329 million pre-tax, non-cash impairment charge in the third quarter of fiscal 2021 related to goodwill, trademarks and other assets in its Better Health vitamins, minerals and supplements business.
- Walmart and its affiliates represented 25% of consolidated net sales in fiscal 2021, 2020 and 2019. The five largest customers accounted for nearly half of sales in each year.
- The estimated fair value of P&G’s 20% interest in the Glad business was $613 million at June 30, 2021; the agreement requires Clorox to purchase that interest for cash at fair value when the venture agreement expires in January 2026, unless extended.
Outlook, management commentary and risks
For fiscal 2022, Clorox anticipated continued uncertainty from COVID-19, changing consumer behavior, competition, elevated commodity, manufacturing and logistics costs, foreign exchange movements and an uncertain macroeconomic environment. Management announced a planned five-year investment of approximately $500 million in digital capabilities and productivity enhancements, including about $90 million in fiscal 2022. The company expects resulting efficiencies to support its supply chain, digital commerce, innovation and brand building over time.
Principal risks highlighted include potential shifts in pandemic-driven demand, supply-chain disruption, cost inflation and the ability to recover costs through pricing; intense competition, including private-label products; dependence on major retailers; and operational, regulatory, cybersecurity and environmental exposures. Clorox disclosed a July 2020 voluntary recall of Poett dilutable cleaning products manufactured in Peru on or before June 30, 2020, and said it was responding to regulatory inquiries and could face further litigation, fines or other liability. Management stated that routine litigation, based on its analysis, was not expected to have a material adverse effect on the consolidated financial statements taken as a whole.
Important facts for investors to verify
- Confirm the intended period: the source is fiscal 2021, ended June 30, 2021, despite the request metadata identifying 2020 Q4.
- Review Exhibit 99.1 for full-year and quarterly revenue, earnings, margins, cash flows, liquidity, debt maturities and segment results; those values are not clearly provided in the supplied text.
- Assess how quickly pandemic-related demand normalizes and whether cost inflation, supply constraints and price increases affect volume and margins.
- Monitor the Better Health impairment and the performance of the vitamins, minerals and supplements business.
- Review developments in the Poett recall, environmental remediation matters and the future Glad venture buyout obligation.